enGene Therapeutics Inc. Warrants closed at $0.22 on Sep 25, down 35.26%, 94.8% below its highest close since Nov 1. Volume of 9.7K shares was 0.72× its 20-day average (below normal).
Split-adjusted performance: -4.3% over one month, -89.2% over six months.
Short interest was 1.7K shares at the Sep 15 settlement, down 63.6% from the prior report (1.0 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −3.9%, revenue growth +9.0%, net margin −231.7%, P/E 20.2×.
No recent articles focused on enGene Therapeutics Inc. Warrants. 1 articles mention it in passing.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
